Leading pharmaceutical company Pfizer Inc has entered into a partnership with Ahmedabad-based Claris Lifesciences Ltd to commercialise sterile injectible drugs that are off-patent and have lost exclusivity in the United States, Canada, Australia, New Zealand and Europe.
These drugs cover a range of therapeutic areas, including anti-infectives, antibiotics and other critical care products.
According to Kelvin Cooper, senior vice-president, portfolio development, established products, Pfizer, “The agreement represents our strategy to transform Pfizer’s off-patent drugs and established products portfolio from becoming a declining business to a growing business. A partnership with Claris will help expand our steriles’ portfolio and provide patients with a wide offering of high quality affordable medicines. Off-patent medicines, including branded generics, represent one of the fastest growth segments in the global pharmaceutical market.”
The research-based biopharma company had visited Claris several times in the past four months before finalising the tie-up.
Pfizer, which has global annual sales of $10 billion for established products, recently expanded an agreement with Aurobindo Pharma to supply finished dosage products. Under the terms, Pfizer has acquired rights to 55 solid oral dose products and five sterile injectable products in the US, Europe and France. Pfizer will supply 60 products in more than 70 countries through Asia, Latin America, Africa and West Asia.
